<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12487">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480324</url>
  </required_header>
  <id_info>
    <org_study_id>107625</org_study_id>
    <nct_id>NCT00480324</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, Reactogenicity &amp; Immunogenicity of the Rotarix Vaccine in Japanese Infants</brief_title>
  <official_title>Efficacy, Safety, Reactogenicity and Immunogenicity Study of the Lyophilised Formulation of Rotarix Vaccine in Healthy Japanese Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is undertaken to provide the regulatory authorities in Japan with immunogenicity,
      efficacy, safety and reactogenicity data of GSK Biologicals' Human Rotavirus [HRV] vaccine,
      given as a 2-dose primary vaccination, in healthy Japanese infants aged approximately 2
      months at the time of the first dose and previously uninfected with HRV. The Protocol
      Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combined diphtheria and tetanus toxoids and acellular pertussis (DTPa) and Hepatitis B (HBV)
      vaccines are allowed to be co-administered along with Rotarix vaccine/Placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains</measure>
    <time_frame>From 2 weeks after Dose 2 up to 2 years of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Severe Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains</measure>
    <time_frame>From 2 weeks after Dose 2 up to 2 years of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>A subject was considered as reporting severe rotavirus gastroenteritis when the subject scored 11 or more on a 20-point scoring system (Vesikari scoring system).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of G1 Type</measure>
    <time_frame>From 2 weeks after Dose 2 up to 2 years of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
Severe RV GE was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of Non-G1 Types</measure>
    <time_frame>From 2 weeks after Dose 2 up to 2 years of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Hospitalized Due to Rotavirus (RV) Gastroenteritis (GE) Caused by the Circulating Wild-type RV Strains</measure>
    <time_frame>From 2 weeks after Dose 2 up to 2 years of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Rotavirus (RV) Gatroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains</measure>
    <time_frame>From Dose 1 up to 2 years of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody Concentration</measure>
    <time_frame>2 months after Dose 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-rotavirus immunoglobulin A antibody concentrations are given as geometric mean concentrations (GMCs). Arbitrary 'zero' values were set in the Placebo Group since the GMC was below the assay cut-off value (20 U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A (IgA) Antibodies</measure>
    <time_frame>2 months after Dose 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion was defined as the appearance of anti-rotavirus immunoglobulin A antibody concentration ≥ 20 units (U)/milliliter (mL) in subjects initially (i.e. prior to the first dose of rotarix) seronegative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Symptoms</measure>
    <time_frame>During the 8-day follow-up period after each dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited symptoms assessed include cough, diarrhoea, fever, irritability, loss of appetite and vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 31-day follow-up period after each dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 2 years of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">765</enrollment>
  <condition>Rotavirus Vaccines</condition>
  <arm_group>
    <arm_group_label>Rotarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotarix</intervention_name>
    <description>Two-dose oral vaccination.</description>
    <arm_group_label>Rotarix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two-dose oral administration.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female infant between, and including, 6 and 14 weeks (42-104 days) of
             age at the time of the first vaccination.

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol should be enrolled in the study

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Born between a gestation period of 36 and 42 weeks inclusive.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             HRV vaccine within 30 days preceding the first dose of HRV vaccine, or planned use
             during the study period.

          -  History of use of experimental rotavirus vaccine.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs since
             birth.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

          -  Uncorrected congenital malformation (such as Meckel's diverticulum) of the
             gastrointestinal tract that would predispose for intussusception.

          -  Any clinically significant history of chronic gastrointestinal disease including any
             uncorrected congenital malformation of the gastrointestinal tract or other serious
             medical condition determined by the investigator.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Previous confirmed occurrence of RV GE.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination (no laboratory testing is required).

          -  A family history of congenital or hereditary immunodeficiency.

          -  Acute disease at the time of enrolment.

          -  Gastroenteritis within 7 days preceding the study vaccine administration.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>14 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Kawamura N et al. Efficacy of human rotavirus vaccine RIX4414 in Japanese infants from 2 weeks post dose 2 up to data lock point. Abstract presented at the 28th meeting of European Society for Paediatric Infectious Diseases (ESPID). Nice, France, 4-8 May 2010.</citation>
  </reference>
  <reference>
    <citation>Kawamura N et al. Efficacy of Human Rotavirus (G1P[8] strain) Vaccine (HRV) RIX4414 in Japanese Infants during the Two-year Efficacy Follow-up Period. Abstract presented at the 114th Annual Meeting of Japan Pediatric Society (JPS). Tokyo, Japan, 12-14 August 2011.</citation>
  </reference>
  <reference>
    <citation>Kawamura N, Tokoeda Y, Oshima M, Okahata H, Tsutsumi H, Van Doorn LJ, Muto H, Smolenov I, Suryakiran PV, Han HH. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine. 2011 Aug 26;29(37):6335-41. doi: 10.1016/j.vaccine.2011.05.017. Epub 2011 Jun 2.</citation>
    <PMID>21640780</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>May 29, 2007</firstreceived_date>
  <firstreceived_results_date>March 30, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rotarix Group</title>
          <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="508"/>
                <participants group_id="P2" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="476"/>
                <participants group_id="P2" count="241"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject’s mother pregnant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rotarix Group</title>
          <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="508"/>
                <measurement group_id="B2" value="257"/>
                <measurement group_id="B3" value="765"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7.7" spread="1.99"/>
                <measurement group_id="B2" value="7.7" spread="2.05"/>
                <measurement group_id="B3" value="7.7" spread="2.01"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="229"/>
                <measurement group_id="B2" value="134"/>
                <measurement group_id="B3" value="363"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="279"/>
                <measurement group_id="B2" value="123"/>
                <measurement group_id="B3" value="402"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains</title>
        <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.</description>
        <time_frame>From 2 weeks after Dose 2 up to 2 years of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="498"/>
                  <measurement group_id="O2" value="250"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains</title>
            <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Severe Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains</title>
        <description>A subject was considered as reporting severe rotavirus gastroenteritis when the subject scored 11 or more on a 20-point scoring system (Vesikari scoring system).</description>
        <time_frame>From 2 weeks after Dose 2 up to 2 years of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="498"/>
                  <measurement group_id="O2" value="250"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Severe Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains</title>
            <description>A subject was considered as reporting severe rotavirus gastroenteritis when the subject scored 11 or more on a 20-point scoring system (Vesikari scoring system).</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of G1 Type</title>
        <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
Severe RV GE was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).</description>
        <time_frame>From 2 weeks after Dose 2 up to 2 years of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="498"/>
                  <measurement group_id="O2" value="250"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of G1 Type</title>
            <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
Severe RV GE was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any RV GE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe RV GE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of Non-G1 Types</title>
        <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).</description>
        <time_frame>From 2 weeks after Dose 2 up to 2 years of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="498"/>
                  <measurement group_id="O2" value="250"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of Non-G1 Types</title>
            <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any RV GE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe RV GE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Hospitalized Due to Rotavirus (RV) Gastroenteritis (GE) Caused by the Circulating Wild-type RV Strains</title>
        <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.</description>
        <time_frame>From 2 weeks after Dose 2 up to 2 years of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="498"/>
                  <measurement group_id="O2" value="250"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Hospitalized Due to Rotavirus (RV) Gastroenteritis (GE) Caused by the Circulating Wild-type RV Strains</title>
            <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Rotavirus (RV) Gatroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains</title>
        <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).</description>
        <time_frame>From Dose 1 up to 2 years of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="508"/>
                  <measurement group_id="O2" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any Rotavirus (RV) Gatroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains</title>
            <description>Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.
Severe rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any RV GE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe RV GE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody Concentration</title>
        <description>Anti-rotavirus immunoglobulin A antibody concentrations are given as geometric mean concentrations (GMCs). Arbitrary 'zero' values were set in the Placebo Group since the GMC was below the assay cut-off value (20 U/mL).</description>
        <time_frame>2 months after Dose 2</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody Concentration</title>
            <description>Anti-rotavirus immunoglobulin A antibody concentrations are given as geometric mean concentrations (GMCs). Arbitrary 'zero' values were set in the Placebo Group since the GMC was below the assay cut-off value (20 U/mL).</description>
            <units>Units per milliliter (U/mL)</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="217.0" lower_limit="109.9" upper_limit="428.6"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A (IgA) Antibodies</title>
        <description>Seroconversion was defined as the appearance of anti-rotavirus immunoglobulin A antibody concentration ≥ 20 units (U)/milliliter (mL) in subjects initially (i.e. prior to the first dose of rotarix) seronegative.</description>
        <time_frame>2 months after Dose 2</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A (IgA) Antibodies</title>
            <description>Seroconversion was defined as the appearance of anti-rotavirus immunoglobulin A antibody concentration ≥ 20 units (U)/milliliter (mL) in subjects initially (i.e. prior to the first dose of rotarix) seronegative.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Symptoms</title>
        <description>Solicited symptoms assessed include cough, diarrhoea, fever, irritability, loss of appetite and vomiting.</description>
        <time_frame>During the 8-day follow-up period after each dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="508"/>
                  <measurement group_id="O2" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Symptoms</title>
            <description>Solicited symptoms assessed include cough, diarrhoea, fever, irritability, loss of appetite and vomiting.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Cough</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="184"/>
                  <measurement group_id="O2" value="92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhoea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="261"/>
                  <measurement group_id="O2" value="125"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Loss of appetite</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="81"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>During the 31-day follow-up period after each dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="508"/>
                  <measurement group_id="O2" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
            <description>Unsolicited adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="279"/>
                  <measurement group_id="O2" value="144"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Up to 2 years of age</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Rotarix Group</title>
            <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="508"/>
                  <measurement group_id="O2" value="257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
            <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rotarix Group</title>
          <description>Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (unspecified)">Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Acute tonsilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Erythema infectiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Teratoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="261" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="261" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (unspecified)">Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (Unspecified)">Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (unspecified)">Upper respiratory tract inflammation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="257"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (unspecified)">Rhinorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (unspecified)">Eczema</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="508"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
